You're Eating Healthy Fats and Still Deficient. Here's the Genetic Reason.

FADS1 encodes an enzyme called delta-5 desaturase. This enzyme’s job is to take shorter-chain polyunsaturated fatty acids (like ALA from flax or chia) and add a double bond, moving them one step closer to their long-chain, highly bioactive forms (EPA and DHA). It’s an essential step in the conversion pipeline.

The rs174537 variant, carried by approximately 30-40% of the population, reduces the efficiency of this enzyme by a significant margin. People with this variant often see 20-30% slower conversion of ALA to EPA, even when dietary intake is adequate. The effect is cumulative. Over months and years, your tissue levels of EPA drift lower than they should be, even if you’re eating salmon and taking supplements.

You experience this as creeping brain fog, joint stiffness, slower wound healing, and a tendency toward mood volatility. Blood work shows low-normal omega-3 levels despite supplementation. Inflammation markers stay elevated. Your doctor may attribute it to stress or age, but the root cause is sitting in your DNA.

FADS2 encodes delta-6 desaturase, the first enzyme in the pathway that converts dietary ALA (short-chain omega-3) into EPA (long-chain omega-3). It’s the rate-limiting step. If FADS2 function is reduced, everything downstream slows down, no matter how much ALA you consume.

The rs1535 variant, present in roughly 35-40% of populations of European ancestry, reduces delta-6 desaturase activity significantly. Carriers often have 25-40% lower capacity to initiate the ALA-to-EPA conversion, which means all subsequent steps in the pathway are starved of substrate. You can eat perfectly and still have inadequate EPA and DHA in your cells.

The lived experience is subtle but pervasive. Your brain feels slower to engage. Joint and muscle recovery after exercise takes longer. Skin quality declines. Mood is flatter. Standard blood tests may show total omega-3 in the “normal” range, but EPA and DHA specifically are low. Doctors often attribute symptoms to general aging or poor sleep, missing the fact that the conversion machinery is simply too slow.

PPARG is a transcription factor that acts like a master switch for how your cells handle fatty acids and inflammation. It activates genes that increase fatty acid uptake into cells, enhance mitochondrial function, and suppress pro-inflammatory signaling. In healthy conditions, PPARG activity keeps omega-6 and omega-3 in balance and prevents chronic inflammation.

Variants in PPARG are associated with reduced receptor sensitivity to activation, meaning your cells are less responsive to signals that would normally trigger healthy fatty acid handling. This creates a shifted metabolic state where pro-inflammatory omega-6 linoleic acid accumulates relative to anti-inflammatory EPA and DHA, even when both are present in adequate amounts. Roughly 20-30% of the population carries variants that impair PPARG function.

You experience this as joint pain, persistent low-grade inflammation, elevated inflammatory markers (CRP, ESR) despite normal lifestyle, and difficulty losing weight or shifting body composition. Omega-3 supplementation helps but doesn’t fully resolve symptoms because the underlying issue is that your cells aren’t listening to the signals that suppress inflammation. You may feel like your body is chronically stuck in a pro-inflammatory state.

APOE encodes the protein that packages and transports fatty acids and cholesterol throughout your bloodstream and into cells. It’s the delivery truck. Your APOE type (E2, E3, or E4, determined by two SNPs: rs429358 and rs7412) fundamentally changes how efficiently your body can transport long-chain omega-3s (EPA and DHA) from your digestive tract into tissues, especially the brain and heart.

APOE4, present in roughly 25-30% of the population in heterozygous form and 2-3% in homozygous form, is less efficient at transporting EPA and DHA into the brain compared to E3 or E2. APOE4 carriers often have lower brain DHA levels despite adequate supplementation, because the transport protein is structurally less suited to carrying these fats across the blood-brain barrier. The result is a functional deficiency at the tissue level despite adequate blood levels.

You may notice this as accelerated cognitive decline with aging, memory fog, difficulty concentrating under stress, or a family history of early cognitive decline. You take omega-3 supplements and your blood levels improve, but the brain fog doesn’t fully resolve. This is because APOE4 affects not just absorption of EPA and DHA, but their distribution to the tissues that need them most.

MTHFR encodes an enzyme that converts folate into its active form (methylfolate), which fuels the methylation cycle. Methylation reactions are upstream of fatty acid metabolism. When methylation is sluggish, the entire cascade of metabolic processes that depend on methylated substrates slows down, including the enzymes that regulate fatty acid balance and PPARG function.

The C677T variant, carried by approximately 40% of the population, reduces enzyme efficiency by 35-40%. This means your methylation cycle runs at a reduced pace, which indirectly impairs the regulation of fatty acid metabolism and leaves you less able to suppress pro-inflammatory signaling. It’s not a direct effect on fatty acid conversion, but it’s a critical upstream control point.

You experience this as worse inflammation in response to high omega-6 intake, slower recovery from exercise, brain fog that worsens when B vitamin intake is low, and a tendency toward mood instability. You may supplement omega-3s and still see persistent inflammation because the methylation machinery that would normally help regulate the inflammatory response is running slow.

The VDR is the lock that vitamin D fits into. Vitamin D is not just a nutrient; it’s a hormone that activates genes controlling inflammation, immune response, calcium homeostasis, and fatty acid metabolism. Without adequate VDR function, your cells can’t hear the vitamin D signal, even if blood levels of vitamin D are technically adequate.

The FokI variant, present in roughly 30-50% of the population depending on ancestry, reduces the efficiency of the vitamin D receptor. VDR variants are associated with functional vitamin D deficiency at the cellular level, which impairs expression of the FADS enzymes themselves and prevents proper regulation of the inflammatory response to omega-6 polyunsaturated fats. You’re essentially stuck with a receptor that doesn’t respond as strongly to available vitamin D.

You notice this as persistent symptoms of vitamin D deficiency despite supplementation: fatigue, joint pain, low mood, slow wound healing, and an exaggerated inflammatory response to dietary omega-6. You take vitamin D and your blood levels rise, but symptoms don’t improve proportionally. This is because the cellular response to vitamin D is blunted. Your cells aren’t listening to the signal.